Agoracom Blog

Valeo Pharma’s $VPH $VPHIF Hesperco Capsules at the Core of Montreal Heart Institute’s Hesperidin Coronavirus Clinical Trial $ $ $ $

Posted by AGORACOM-JC at 8:21 AM on Wednesday, February 17th, 2021
Valeo Pharma (@valeo_pharma) | Twitter
  • Montreal Heart Institute study to evaluate the ability of hesperidin, the medicinal ingredient in Hesperco™ capsules, to reduce the severity of symptoms and the need for hospitalization in COVID-19 patients
  • Hesperidin interferes / inhibits 2 key proteins of SARS-CoV-2 necessary for entry and infection of cells, suggesting that hesperidin may disrupt the replication rate of the virus and enable infected patients to build natural immunity
  • Hesperidin’s safety profile and immune-modulatory activity make it a highly promising molecule to intervene at various stages of the COVID-19 infection process
  • Hesperco TM capsules contain 500mg of high purity concentrated hesperidin

MONTREAL , Feb. 17, 2021 – Valeo Pharma Inc . ( CSE:VPH) (OTCQB:VPHIF) (FSE:VP2 ) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company and its Hesperco™ development partner, Ingenew Pharma Inc. (“Ingenew”), are pleased to announce that Hesperco TM capsules, approved by Health Canada for immune support, will be at the core of the Montreal Heart Institute’s (“MHI”) clinical trial, “The Hesperidin Coronavirus Study”.

The MHI’s study will evaluate the effect of hesperidin on COVID-19 symptoms and its ability to reduce disease severity and the need for hospitalization in patients with COVID-19. The randomized, double-blind, placebo controlled study will enroll 216 confirmed COVID-19 symptomatic patients.

“The immune support properties of hesperidin, the medicinal ingredient contained in HESPERCO™ capsules, and its efficacy against other coronavirus strains are well documented in scientific literature. We are extremely proud to contribute in the fight against the COVID-19 virus with the prestigious MHI and our development partner Ingenew”, said Steve Saviuk , Valeo’s CEO. “Our involvement in this study aligns well with our vision to build a Canadian anchor pharmaceutical company and continued commitment to provide Canadian healthcare professionals and patients with innovative solutions to improve quality of life”.

Commenting on the  Montreal Heart Institute’s Hesperidin Coronovirus Study, Pierre Laurin , President and CEO of Ingenew, said: “We are pleased that MHI’s scientists  concur with our scientific findings.”

Read More:

Tags: , , , , , , , , ,

Comments are closed.